Trials / Completed
CompletedNCT00113529
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the maximum tolerated dose and overall safety and tolerability of sunitinib \[SU011248\] administered in combination with gefitinib (Iressa) for the treatment of patients with metastatic renal cell carcinoma (Phase 1). To assess antitumor activity of the combination of gefitinib and sunitinib (Phase 2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib + Sunitinib | Until disease progression or unacceptable toxicity. |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2007-09-01
- Completion
- 2008-10-01
- First posted
- 2005-06-09
- Last updated
- 2011-08-29
- Results posted
- 2010-03-31
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00113529. Inclusion in this directory is not an endorsement.